US investor backs SIMPLE antibody discovery firm in €27.5m fundraising
This article was originally published in Scrip
Executive Summary
arGEN-X, a small European biotech company focused on the discovery and development of human monoclonal antibodies from its SIMPLE antibody discovery platform, has closed a €27.5 million ($37 million) series B fundraising round, which was oversubscribed. The fundraising was co-led by OrbiMed Advisors of the US and Seventure Partners of France.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.